Posted by Michael Wonder on 30 Jul 2022
Amylyx Pharmaceuticals announces Albrioza is now available in Canada for the treatment of amyotrophic lateral sclerosis
29 July 2022 - Amylyx Pharmaceuticals today announced that Albrioza (sodium phenylbutyrate and ursodoxicoltaurine) is now commercially available in Canada for people living with amyotrophic lateral sclerosis.
Albrioza (also known as AMX0035) is an oral fixed-dose combination therapy that may reduce neuronal cell death as a stand-alone therapy or when added to existing treatments.
Amylyx filed reimbursement submissions to CADTH and Institut national d’excellence en santé et en services sociaux (INESSS) in Quebec as part of an aligned health technology assessments review with Health Canada in parallel with the regulatory process to reduce the timelines required for patient access.
